| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.10. | SL Science Holding Limited Non-GAAP EPS of $0.00, revenue of $1.38B | 1 | Seeking Alpha | ||
| SL SCIENCE Aktie jetzt für 0€ handeln | |||||
| 26.10. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 26.10. | SL Science Holding Limited Reports First Half 2026 Financial Results | 1 | GlobeNewswire (USA) | ||
| 09.10. | SL Science Holding Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 24.09. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.09. | SL Science Holding Limited: SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing Gamma delta T Cells Target Chemotherapy-Resistant Glioblastoma | 4 | GlobeNewswire (USA) | ||
| 02.09. | SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company | 1 | GlobeNewswire (USA) | ||
| 27.08. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.08. | SL Science licensor files exosome drug master file with FDA | 3 | Investing.com | ||
| 27.08. | SL Science Holding Limited: SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform | 521 | GlobeNewswire (Europe) | TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular... ► Artikel lesen | |
| 17.07. | SL Science presents glioblastoma treatment data at WCP 2026 | 3 | Investing.com | ||
| 17.07. | SL Science präsentiert Daten zur Glioblastom-Behandlung auf Weltkongress | 1 | Investing.com Deutsch | ||
| 17.07. | SL Science Holding Limited: SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology | 1 | GlobeNewswire (USA) | ||
| 10.07. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.07. | SL Science seeks orphan drug status for brain cancer therapy | 4 | Investing.com | ||
| 10.07. | Hirntumortherapie: SL Science beantragt Orphan-Drug-Status | 3 | Investing.com Deutsch | ||
| 10.07. | SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma | 770 | GlobeNewswire (Europe) | Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative... ► Artikel lesen | |
| 18.06. | SL Science Holding Limited Reports Full Year 2025 Financial Results | 621 | GlobeNewswire (Europe) | Taipei, TAIWAN, June 18, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative... ► Artikel lesen | |
| 18.06. | SL Science Holding Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 15.06. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 11 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TARSUS PHARMACEUTICALS | 78,68 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| IMMUNOME | 17,610 | 0,00 % | Immunome Analysts Cut Their Forecasts After Q3 Results | ||
| DISC MEDICINE | 76,59 | 0,00 % | Disc Medicine auf der UBS-Biopharmakonferenz: Pipeline gewinnt an Dynamik | ||
| ABSCI | 7,475 | 0,00 % | Absci Corp. (ABSI) Gets Downgraded. Here's How Much | ||
| ADMA BIOLOGICS | 13,470 | 0,00 % | ADMA Biologics (NDQ:ADMA): The Antibody Factory, The Short Seller Attack, And The Earnings That Followed | ||
| KINIKSA PHARMACEUTICALS | 94,23 | 0,00 % | TD Cowen raises Kiniksa stock price target to $115 on Arcalyst growth | ||
| ERASCA | 15,100 | 0,00 % | Erasca, Inc.: Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise | ||
| BEAM THERAPEUTICS | 20,930 | -0,05 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 125,81 | 0,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 18,570 | 0,00 % | Unlearn AI: Unlearn and Structure Therapeutics Collaborate to Apply AI-Generated Digital Twins in Obesity Research | Retrospective analysis at ObesityWeek will explore how AI-based modeling can provide context for longer-term obesity study results SAN FRANCISCO, CA / ACCESS Newswire / November 12, 2026 / Unlearn today... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,790 | 0,00 % | Amylyx: Avexitide-Studie erreicht primären Endpunkt bei postbariatrischer Hypoglykämie | ||
| ENLIVEN THERAPEUTICS | 47,600 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| QIAGEN | 45,305 | -0,01 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 2,905 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| BICARA THERAPEUTICS | 9,750 | 0,00 % | Stifel senkt Kursziel für Bicara Therapeutics wegen höherer OpEx-Schätzungen |